Dietary n-3 and n-6 polyunsaturated fatty acid intake interacts with FADS1 genetic variation to affect total and HDL-cholesterol concentrations in the Doetinchem Cohort Study

American Journal of Clinical Nutrition

Volumn 92, Issue 1, 2010, Pages 258-265

  Lu, Yingchang ^a,b   Feskens, Edith J M ^a   Dollé, Martijn E T ^b   Imholz, Sandra ^b   Verschuren, W M Monique ^b   Müller, Michael ^a   Boer, Jolanda M A ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; ACYL COENZYME A DESATURASE; APOLIPOPROTEIN B; FADS1 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FAT INTAKE; FEMALE; GENE CLUSTER; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; 3' UNTRANSLATED REGION; BLOOD; CHOLESTEROL INTAKE; GENETICS; HUMAN GENOME; METABOLISM; MULTIGENE FAMILY; NETHERLANDS;

3' UNTRANSLATED REGIONS; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; COHORT STUDIES; FATTY ACID DESATURASES; GENETIC VARIATION; GENOME, HUMAN; GENOTYPE; HUMANS; MULTIGENE FAMILY; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77954613710     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.2009.29130     Document Type: Article

References (66)

1. Cho HP, Nakamura MT, Clarke SD. Cloning, expression, and nutritional regulation of the mammalian Delta-6 desaturase. J Biol Chem 1999;274:471-7.
2. Cho HP, Nakamura M, Clarke SD. Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J Biol Chem 1999;274:37335-9. (Pubitemid 30016815)
3. Marquardt A, Stohr H, White K, Weber BH. cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase family. Genomics 2000;66:175-83. (Pubitemid 30429752)
4. Pédrono F, Blanchard H, Kloereg M, et al. The fatty acid desaturase 3 gene encodes for different FADS3 protein isoforms in mammalian tissues. J Lipid Res 2010:51:472-9.
5. Blanchette M, Kent WJ, Riemer C, et al. Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res 2004;14:708-15.
6. Schaeffer L, Gohlke H, Muller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006;15:1745-56.
7. Malerba G, Schaeffer L, Xumerle L, et al. SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. Lipids 2008;43:289-99.
8. Xie L, Innis SM. Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J Nutr 2008;138:2222-8.
9. Martinelli N, Girelli D, Malerba G, et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 2008;88:941-9.
10. Rzehak P, Heinrich J, Klopp N, et al. Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. Br J Nutr 2009;101:20-6.
11. Gieger C, Geistlinger L, Altmaier E, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008;4:e1000282.
12. Tanaka T, Shen J, Abecasis GR, et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet 2009;5:e1000338.
13. Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009;41:47-55.
14. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009;41:56-65.
15. Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet 2009;41:35-46.
16. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989;30:785-807.
17. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(suppl):1645S-54S.
18. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91.
19. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12-24.
20. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003;77:1146-55.
21. Theobald HE, Chowienczyk PJ, Whittall R, Humphries SE, Sanders TA. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr 2004;79:558-63.
22. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002;51:2377-86.
23. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001;358:1356-60.
24. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 2005;6:287-98.
25. Verschuren WM, Blokstra A, Picavet HS, Smit HA. Cohort profile: the Doetinchem Cohort Study. Int J Epidemiol 2008;37:1236-41.
26. Ocke MC, Bueno-de-Mesquita HB, Pols MA, Smit HA, van Staveren WA, Kromhout D. The Dutch EPIC food frequency questionnaire. II. Relative validity and reproducibility for nutrients. Int J Epidemiol 1997;26(suppl 1):S49-58.
27. NEVO Foundation. Dutch Food Composition Table 1996. The Hague, Netherlands Nutrition Centre, 1996 (in Dutch).
28. Lu Y, Dolle ME, Imholz S, et al. Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations. J Lipid Res 2008;49:2582-9.
29. van den Berg SW, Dolle MET, Imholz S, et al. Genetic variations in regulatory pathways of fatty acid and glucose metabolism are associated with obesity phenotypes: a population-based cohort study. Int J Obes (Lond) 2009;33:1143-52.
30. Kattermann R, Jaworek D, Moller G, et al. Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem 1984;22:245-51.
31. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977;23:882-4.
32. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
33. Myers GL, Cooper GR, Henderson O, Hassemer DJ, Kimberly M. Standardization of lipid and lipoprotein measurements. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. Washington, DC: AACC Press, 1997.
34. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995;41:1414-20.
35. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995;41:1427-33.
36. Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 2003;100:12027-32.
37. Xu H, Gregory SG, Hauser ER, et al. SNPselector: a web tool for selecting SNPs for genetic association studies. Bioinformatics 2005;21:4181-6. (Pubitemid 41672110)
38. Hicks AA, Pramstaller PP, Johansson A, et al. Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet 2009;5:e1000672.
39. Lall S, Grun D, Krek A, et al. A genome-wide map of conserved microRNA targets in C. elegans. Curr Biol 2006;16:460-71.
40. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
41. Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. Nat Genet 2007;39:1202-7.
42. Schadt EE, Molony C, Chudin E, et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 2008;6:e107.
43. Plaisier CL, Horvath S, Huertas-Vazquez A, et al. A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. PLoS Genet 2009;5:e1000642.
44. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis 1990;10:668-71.
45. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis 1993;104:159-71.
46. Elovson J, Chatterton JE, Bell GT, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988;29:1461-73.
47. Motoyama KR, Curb JD, Kadowaki T, et al. Association of serum n-6 and n-3 polyunsaturated fatty acids with lipids in 3 populations of middle-aged men. Am J Clin Nutr 2009;90:49-55.
48. Botolin D, Wang Y, Christian B, Jump DB. Docosahexaneoic acid (22:6, n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. J Lipid Res 2006;47:181-92.
49. Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 2008;19:242-7.
50. Xu J, Nakamura MT, Cho HP, Clarke SD. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem 1999;274:23577-83.
51. Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994;77:53-62.
52. Wilkinson J, Higgins JA, Fitzsimmons C, Bowyer DE. Dietary fish oils modify the assembly of VLDL and expression of the LDL receptor in rabbit liver. Arterioscler Thromb Vasc Biol 1998;18:1490-7.
53. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997;94:4318-23.
54. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997;94:4312-7.
55. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397-403.
56. Pawar A, Jump DB. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes. J Biol Chem 2003;278:35931-9. (Pubitemid 37139911)
57. Duval C, Muller M, Kersten S. PPARalpha and dyslipidemia. Biochim Biophys Acta 2007;1771:961-71.
58. Akiyama TE, Sakai S, Lambert G, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002;22:2607-19.
59. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008;47:147-55.
60. Hussein N, Ah-Sing E, Wilkinson P, Leach C, Griffin BA, Millward DJ. Long-chain conversion of [13C]linoleic acid and alpha-linolenic acid in response to marked changes in their dietary intake in men. J Lipid Res 2005;46:269-80.
61. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr 2006;84:44-53.
62. Liou YA, King DJ, Zibrik D, Innis SM. Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J Nutr 2007;137:945-52.
63. Volcik KA, Nettleton JA, Ballantyne CM, Boerwinkle E. Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2008;87:1926-31.
64. Warnick GR, Nakajima K. Fasting versus nonfasting triglycerides: implications for laboratory measurements. Clin Chem 2008;54:14-6.
65. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-56.
66. Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000;15:395-9.